Multiple myeloma

What Is Multiple Myeloma?

Multiple myeloma is a cancer of plasma cells, the antibody producing white blood cells normally found within the bone marrow, and it rarely appears suddenly out of nowhere, typically developing instead through a recognizable, multistage disease spectrum.¹

This spectrum begins with a condition called monoclonal gammopathy of undetermined significance, present in roughly five percent of the general population over age fifty, which carries a modest one percent per year risk of progressing toward malignancy.¹

An intermediate stage called smoldering multiple myeloma sits between this earlier, essentially harmless condition and full symptomatic multiple myeloma, carrying a considerably higher progression risk, particularly during the first several years following diagnosis.¹

Smoldering myeloma is the asymptomatic intermediary between monoclonal gammopathy of undetermined significance and multiple myeloma.
National Center for Biotechnology Information

Symptoms

Both monoclonal gammopathy of undetermined significance and smoldering multiple myeloma are, by definition, asymptomatic conditions, identified only through blood testing performed for another reason or as part of targeted screening.¹

Symptoms typically emerge only once the disease has progressed to symptomatic multiple myeloma, at which point evidence of organ damage, including bone disease, kidney impairment, or anemia, becomes clinically apparent.¹

Because early stages produce no symptoms, careful monitoring after an incidental diagnosis of monoclonal gammopathy or smoldering myeloma plays an essential role in catching progression to symptomatic disease as early as possible.

Causes

Multiple myeloma develops when a clone of abnormal plasma cells accumulates within the bone marrow, progressively increasing in proportion as the disease advances along its natural spectrum.²

Smoldering multiple myeloma is specifically defined by the presence of at least ten percent clonal plasma cells within the bone marrow, along with elevated monoclonal protein levels in the blood or urine, occurring in the absence of any organ damage.²

Several measurable disease characteristics help predict which patients with early stage disease are more likely to progress, including the concentration of monoclonal protein, the degree of bone marrow plasma cell involvement, and the specific antibody subtype involved.³

Risk Factors

An abnormal ratio between two types of light chain proteins produced by plasma cells represents one of the most important laboratory findings used to stratify progression risk in patients with early stage disease.³

A risk stratification model developed at the Mayo Clinic combines monoclonal protein concentration, bone marrow plasma cell percentage, and light chain ratio abnormality to categorize patients into distinct risk groups, with patients meeting all three high risk criteria facing roughly a seventy six percent chance of progression within five years.³

Additional risk indicators include detection of multiple focal lesions on whole body MRI and evidence of an evolving clinical course across consecutive followup visits, both of which further refine individual progression risk assessment.³

Complications

Once multiple myeloma progresses to symptomatic disease, patients commonly experience skeletal damage, kidney impairment, and anemia, reflecting the cumulative effect of abnormal plasma cell proliferation on multiple organ systems.¹

For patients treated with modern combination therapy, achieving a state called minimal residual disease negativity, meaning no detectable cancer cells remain despite highly sensitive testing, has been strongly linked to meaningfully longer periods without disease progression.⁴

Patients who remain minimal residual disease positive despite treatment face a higher risk of eventual relapse, making this measurement an increasingly important tool for guiding ongoing treatment decisions after initial therapy.⁴

Treatment

Quadruplet treatment regimens, combining a monoclonal antibody such as daratumumab with three other established myeloma medications, have demonstrated better outcomes compared to standard three drug combinations among appropriate patients.⁵

Adding daratumumab to standard treatment has been shown to triple the rate of minimal residual disease negativity in certain patient populations, and those who achieve this deeper response experience significantly longer periods without disease progression compared to patients who remain minimal residual disease positive.⁴

Following initial treatment and stem cell transplantation, maintenance therapy with lenalidomide represents the current standard of care, though for patients who remain minimal residual disease positive after transplant, lenalidomide alone may not be sufficient, prompting interest in more intensive maintenance approaches for this specific group.⁵

Prevention

Because multiple myeloma arises from a progression that begins with an essentially asymptomatic precursor condition, there is no established way to prevent the initial development of monoclonal gammopathy of undetermined significance.

For patients already identified with monoclonal gammopathy or smoldering myeloma, regular monitoring using validated risk stratification tools allows earlier detection of progression, supporting timely treatment initiation before significant organ damage occurs.³

Ongoing minimal residual disease monitoring after treatment allows clinicians to identify patients at higher relapse risk, supporting more individualized decisions about maintenance therapy intensity and duration.⁴

Why Visual Communication Matters for Multiple Myeloma

Explaining how multiple myeloma develops through a recognizable, multistage spectrum, beginning with an essentially harmless finding and only sometimes progressing to active cancer, requires visuals that help patients understand exactly where they fall along this continuum.

Pharmaceutical companies, hematology and oncology practices, and patient education organizations rely on clear illustration and animation to explain multiple myeloma and support informed treatment decisions.

• Illustrating the disease spectrum from precursor conditions to active myeloma
• Animating risk stratification tools used to predict disease progression
• Explaining quadruplet therapy and the mechanism of action of daratumumab
• Visualizing minimal residual disease testing and its role in treatment decisions
• Supporting patient education on monitoring and maintenance therapy
• Creating training materials for hematology, oncology, and transplant clinicians

How Biotic Artlab Supports Multiple Myeloma Communication

We work with pharmaceutical companies, hematology and oncology practices, and patient advocacy organizations to create scientifically accurate visuals that make multiple myeloma and its treatment easier to understand.

• Custom 3D animations of the disease spectrum from MGUS to active myeloma
• Detailed illustrations of risk stratification models and progression prediction
• Mechanism of action animations for quadruplet therapy and daratumumab
• Patient facing materials on minimal residual disease testing and maintenance therapy
• Clinical training content for hematology, oncology, and transplant teams
• Conference presentations and marketing visuals for blood cancer audiences

Frequently Asked Questions

Does everyone with MGUS develop multiple myeloma?

No, monoclonal gammopathy of undetermined significance carries only a modest one percent per year risk of progressing to malignancy.¹

What is smoldering multiple myeloma?

It is an intermediate, asymptomatic stage between MGUS and active multiple myeloma, carrying a higher but still variable risk of progression depending on individual risk factors.¹

What is minimal residual disease testing?

It is a highly sensitive test that detects whether any cancer cells remain after treatment, with negative results linked to significantly better long term outcomes.⁴

What is quadruplet therapy?

Quadruplet therapy combines four medications, including a monoclonal antibody such as daratumumab, and has shown better outcomes than standard three drug combinations in appropriate patients.⁵

What is maintenance therapy after myeloma treatment?

Lenalidomide maintenance is the current standard following transplant, though patients who remain minimal residual disease positive may need more intensive approaches.⁵

How is progression risk predicted in early stage disease?

Risk stratification models combine monoclonal protein levels, bone marrow plasma cell percentage, and light chain ratio abnormalities to estimate individual progression risk.³

Have a Project in Mind? Contact Us.

If you are developing patient education materials, clinical training content, or marketing visuals related to multiple myeloma or hematologic oncology, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.

References

1. National Center for Biotechnology Information. Smoldering Multiple Myeloma, Observation Versus Control Versus Cure.
2. National Center for Biotechnology Information. Smoldering Multiple Myeloma, Evolving Diagnostic Criteria and Treatment Strategies.
3. National Center for Biotechnology Information. Risk Stratification of Smoldering Multiple Myeloma Incorporating Revised IMWG Diagnostic Criteria.
4. National Center for Biotechnology Information. Minimal Residual Disease Response Adapted Therapy in Newly Diagnosed Multiple Myeloma.
5. National Center for Biotechnology Information. How First Line Therapy Is Changing in Transplant Eligible Multiple Myeloma Patients.

Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, emergency care, or individualized advice from a qualified healthcare professional.